ImmunityBio reports Q4 EPS (6c), consensus (10c)

Reports Q4 revenue $38.29M, consensus $37.78M. “Our 2025 financial results reflect the growing clinical adoption of Anktiva as a foundational backbone of immunotherapy for bladder cancer,” said Richard Adcock, president and CEO of ImmunityBio (IBRX). “Our partnership with Accord Healthcare deploys over 100 commercial professionals across 30 European countries, and our collaboration with BioPharma & Cigalah positions us for rapid commercial execution in Saudi Arabia and the broader MENA region. With subsidiaries now established in Dublin and the Kingdom of Saudi Arabia, we have the infrastructure to support sustained commercial growth across all 33 countries where Anktiva is authorized. As we advance toward initial international commercial activities, we remain focused on disciplined execution: completing enrollment in our BCG-naive randomized trial with a BLA filing targeted by Q4 2026, expanding the Anktiva label into lung cancer and lymphopenia, and converting our 700% revenue growth trajectory into durable, long-term value for shareholders.”